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ABSTRACT
Inflammation plays an important role to the process of prostate carcinogenesis by increasing the rate of cell proliferation, 
which contributes to an aggressive tumour phenotype. Cyclooxygenase-2 (COX-2) has been found overexpressed in 
various types of cancer cells including prostate. The aim of this study was to investigate the COX-2 expressions in different 
types of human prostate tissues. Paraffin-embedded prostate tissues from 263 samples were examined for the expression 
of COX-2 marker by immunohistochemistry method. COX-2 was found highly expressed in prostate adenocarcinoma 
(p=0.001) as compared to benign and normal tissues. The score of COX-2 expressions in most of normal prostate was 
weak 49 (77.8%), while only 16 (16%) of BPH showed strong expression. 56 cases (56%) prostate cancer showed strong 
COX-2 expression. Prostate cancer cases showed significant differences in staining patterns as tumour grade increased. 
In addition, COX-2 expression was significantly correlated with Gleason score in cancerous tissues. This study suggests 
that COX-2 overexpression is associated with prostate cancer and higher grade tumour.
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ABSTRAK
Inflamasi memainkan peranan penting dalam proses pembentukan kanser prostat melalui peningkatan kadar pembahagian 
sel. Inflamasi juga bertanggungjawab dalam pembentukan fenotip kanser prostat yang lebih agresif. Siklooksigenase-2 
(COX-2 didapati diekspres lebih tinggi daripada aras biasa dalam pelbagai jenis sel kanser termasuk prostat. Tujuan 
kajian ini dijalankan adalah untuk mengkaji pengekspresan COX-2 dalam tisu prostat manusia yang berbeza. Sebanyak 
263 tisu prostat tertanam  parafin telah digunakan untuk mengkaji aras pengekspresan penanda COX-2 melalui kaedah 
imunohistokimia. Pengekspresan COX-2 didapati lebih tinggi dalam tisu adenokarsinoma prostat (p=0.001) berbanding 
tisu benigna dan tisu prostat yang normal. Kebanyakan tisu prostat normal mengekspres COX-2 yang lemah 49 (77.8%) 
dan hanya 16 (16%) tisu BPH menunjukkan pengekspresan COX-2 yang kuat. Manakala, 56 (56%) tisu kanser prostat 
menunjukkan pengekspresan COX-2 yang kuat. Tisu kanser prostat juga menunjukkan perbezaan corak perwarnaan 
COX-2 yang signifikan dengan peningkatan gred tumor. Selain itu, pengekspresan COX-2 menunjukkan perhubungan 
yang signifikan dengan skor Gleason dalam tisu kanser. Kajian ini mencadangkan bahawa terdapat hubungan antara 
pengekspresan COX-2 yang sangat tinggi dengan kanser prostat dan tumor gred tinggi.
Kata kunci: Adenikarsinoma prostat; siklooksigenase-2 (COX-2); imunohistokimia; inflamasi; pengekspresan
INTRODUCTION
Prostate adenocarcinoma (PCa) is one of the most 
frequently diagnosed cancers among males in Malaysia. 
A report by National Cancer Registry (2008) showed that, 
prostate cancer is the fourth frequent cancer occurred and 
accounted for 7.3% of the total cancers occurrence among 
males. Out of total cases, the majority of morphologically 
reported cases were adenocarcinoma which is 96%. 
Today diagnosis of prostate cancer is commonly based on 
morphological interpretation by use of cell architecture, 
nuclear features and presence or absence of basal cell 
layer. Nevertheless, this method is usually not adequate in 
equivocal cases in which it might require histopathologists 
to use immunohistochemistry (IHC) staining to resolve the 
differential diagnosis (Varma & Jasani 2005). Despite of 
the clinical importance of prostate cancer, understanding 
of mechanism underlying development and progression of 
this disease is poorly understood. Many researches have 
suggested that inflammation was linked to the development 
of tumours in several organs, including the prostate itself 
(Weitzman & Gordon 1993). Cyclooxygenase (COX), was 
referred as prostaglandin (PG) endoperoxidase synthase, 
is an enzyme that converts arachodonic acids to PGs and 
other eicosanoids. COX exists in two isoforms, namely 
COX-1 and COX-2. COX-1 is expressed constitutively 
in many tissues and cell types and involved in normal 
cellular physiological functions. Meanwhile, COX-2 exists 
as pro-inflammatory in nature and inducible by variety 
of factors, including growth factors, cytokines, tumour 
promoters and mitogens (Herschman 1991). Aberrant 
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or increased expression of COX-2 has been described 
in most of human carcinomas such as gastric cancer, 
esophageal carcinoma, hepatocellular carcinoma, head 
and neck squamous cell carcinoma, lung carcinoma and 
breast carcinoma (Chan et al. 1999; Hwang et al. 1998; 
Kazuhiko et al. 1998; Koga et al. 1999; Wolff et al. 1998; 
Zimmermann et al. 1999) Additional studies showed 
elevated level of COX-2 induces cancer cell proliferation, 
inhibits apoptosis, promotes tumour cell vascularization, 
as well as increases metastatic potential (Kakiuchi et al. 
2002; Sheng et al. 2001). Early studies on relationship 
of COX reported that COX-1 and COX-2 expression levels 
were found to be approximately equal in various human 
tissues (O’Neill & Ford-Hutchinson 1993). In year 
2000, a study which has been done in Japan proved that 
COX-2 was highly expressed in prostate adenocarcinoma 
compared to benign and normal prostate (Yoshimura et al. 
2000). Song et al. (2002) demonstrated increased COX-2 
expression in prostate cancer cells in vitro correlates with 
a decreased in the apoptotic index. Additionally, studies 
on animal models of prostate cancer suggested a link 
between arachidonic acid and its precursor, linoleic acid 
which is the major ingredient of animal fat and vegetable 
oils in diet that contribute to increase of risk of getting 
prostate cancer (Bosland et al. 1999). In this study, we 
aimed to examine the expression of COX-2 in series of 
normal, BPH and prostate adenocarcinoma cases using 
immunohistochemistry as a method to determine the 
role of COX-2 in prostate carcinogenesis and its possible 
associations with some clinocopathological parameters 
of malignant cases.
MATERIALS AND METHODS
PATIENT SAMPLES
A total of 263 paraffin embedded specimens were obtained 
between year 2006 and 2008. The specimens selected 
for this study consist of 63 normal prostate tissues, 100 
each of BPH and PCa. Normal prostate were obtained 
from post-mortem of dead body which was died due to an 
accident. Whereas, the benign and prostate cancer tissues 
specimens were obtained from patient who underwent 
radical prostatectomy. Ethical approval was obtained from 
Research Ethic Committee of Universiti Putra Malaysia 
(UPM), National Medical Research Registration (NMRR) 
and HKL. The tumour histopathology was classified by 
Gleason grading and scored as low group; Gleason 6 to 
7 and high group; Gleason 8 to 9. Tumour volume was 
classified as low amount, ≤ 5% and high amount, >5%. 
Pre-treatment PSA were grouped as either ≤ 4.0 ng/mL 
and >4.0 ng/mL.
IMMUNOHISTOCHEMISTRY
COX-2 immunohistochemistry staining was done using 
the DAKO REAL EnVision kit (Dako, Ca, USA). Formalin-
fixed and paraffin-embedded blocks were sectioned at 4 
μm thickness and preceded with Hematoxyline and Eosin 
(H & E) staining to confirm the diagnosis before the 
immunohistochemistry procedure. Sections were mounted 
onto poly-L-lysine glass slide and dried overnight at room 
temperature. Then, sections were dewaxed with absolute 
xylene and rehydrated with gradient alcohol and lastly run 
under tap water. Antigens were retrieved by microwaving 
at 1000 W for 10 min high temperature followed by 10 
min medium low temperature in citrate buffer (0.01 M, pH 
6.0). After cooled down at room temperature for 20 min, 
sections endogenous peroxidase activity was inactivated 
in 3% H2O2 for 5 min. Then, sections were rinsed with 
phosphate buffer saline (PBS) 2 times for 5 min followed 
by 1 h incubation with monoclonal mouse anti-human 
COX-2 (clone CX-294, Dako, USA) at a dilution 1:100. 
Secondary antibody detection system (Dako, EnVision+ 
System-HRP labeled, Dako, USA) was added to the 
sections and incubated for 30 min at room temperature. 
Finally, diaminobenzidine (Dako, USA) was used as a 
chromogen to verify immunoreactions and followed by 
counterstaining by using hematoxylin. Negative control 
was processed simultaneously from the same samples 
and protocol but primary antibody step was replaced by 
antibody diluents. Colon adenocarcinoma sections were 
used as a positive control because this tissue is well 
known to express COX-2. 
COX-2 EXPRESSION ANALYSIS
A representative area with 500 tumour cells was assessed 
for the positive and negative staining by two pathologists 
that were blinded from the original diagnosis. The 
degree of staining intensity scored was recorded as 0 
to 4+ by using ten randomly ocular fields under X200 
magnification. The extent and intensity of positive tumour 
cells was graded as 0, none; 1+, weak; 2+, moderate; 
3+, strong; and 4+, very strong (Yoshimura et al. 2000). 
Positive staining was considered if more than one percent 
of tumour cells stained and together with membranous, or 
cytoplasmic and/or diffuse (membranous + cytoplasmic) 
staining pattern were detected. Intensity score was 
further grouped as low (0 - 2+) and high (3+ - 4+) COX-
2 expression in order to see any association with the 
clinicopathological parameters. All slides were evaluated 
without any knowledge of the patient’s information and 
clinical reports.
STATISTICAL ANALYSIS
Data were recorded and statistically analysed using SPSS for 
Windows Version 17.0 (Chicago, USA) and the statistical 
results were considered significant when the P value is 
less than 0.05 at 95% confidence intervals. Mann-Whitney 
test was used to compare the expression of COX-2 between 
normal, BPH and PCa. Chi-square test was also used to see 
the association between clinicopathological variables with 
COX-2 expressions. 
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RESULTS AND DISCUSSION
Total specimens included in this study were in the ages 
of 28 to 91 (mean age, 64.54±10.8 years). Expression of 
COX-2 was compared between normal, BPH and PCa tissues. 
Of the total 100 PCa cases; 37 cases were Gleason 6, 37 
cases had Gleason 7, 10 cases were Gleason 8 and the other 
16 cases had Gleason 9. There was constitutively weak 
COX-2 expression observed in all cases (77.8%) of normal 
prostate. Weak expression was also seen in 84 cases (84%) 
of BPH and 44 cases (44%) of PCa. In contrast, strong COX-
2 expression was detected in 56 of PCa cases (56%) with 
the score of 3+ to 4+. Only 16 cases (16%) of BPH showed 
strong COX-2 expression. Whereas none of the normal 
prostate tissues showed strong COX-2 expression. There is 
a significant different of COX-2 expression bewteen normal, 
BPH and PCa, COX-2 expression was found constitutively 
greater in PCa (p<0.001) than benign and normal prostate 
(Table 1). Three patterns of staining were found in COX-
2 expression, in which from membranous, cytoplasmic 
and diffuse (mix of both patterns). Staining pattern was 
concentrated around membrane of the cells and scattered 
into cytoplasmic region. COX-2 was expressed in glandular 
epithelial cells but not in the stroma (Figure 1(a)-1(f)). 
 Majority of normal prostate cases (92.1%) and 
BPH (76%) cases exhibited a membranous staining 
pattern. None of both cases however showed diffuse 
staining pattern. In contrast, 32 (32%) PCa cases showed 
cytoplasmic staining and 28 (28%) cases showed diffused 
staining pattern (Table 2). Membranous staining pattern 
was seen in 32 (86.5%) in Gleason 6 cases whereas 21 
(56.8%) cases of Gleason 7 showed cytoplasmic staining 
pattern. In contrast, 6 (60%) cases of Gleason 8 and 14 
(87.5%) cases of Gleason 9 exhibited diffused staining 
patterns (Table 3). Generally, variety of staining pattern 
exhibited in PCa cases was correlated with increasing 
tumour grade (p=0.0001)(Table 3). 
 Beside that, association between COX-2 expression 
with clinicopathological parameters (age, PSA level, 
Gleason score and tumour amount) was also studied 
and grouped into certain cut-off points (Wang et al. 
TABLE 1. Distribution of COX-2 expression in normal, BPH and PCa cases
 
Distribution of COX-2 staining intensity
 
p
Score 0 1 2 3 4  
TotalTissue type  
Normal
BPH
PCa
0 (0%)
7 (7%)
0
49 (77.8%)
36 (36%)
10 (10%)
14 (22.2%)
41 (41%)
34 (34%)
0 (0%)
15 (15%)
41 (41%)
0 (0%)
1 (1%)
15 (15%)
63 (100%)
100 (100%)
100 (100%)
 
0.001
0.000
FIGURE 1. Immunohistochemical detection of COX-2 in human prostate tissues (X 200) (a) Normal prostate cell shows weak and 
membranous staining of COX-2, (b) BPH shows moderate membranous staining of COX-2, (c) PCa Gleason 6 shows weak and cytoplasmic 
staining of COX-2, (d) PCa Gleason 7 shows moderate to strong and membranous to cytoplasmic staining of COX-2, (e) PCa Gleason 8 
shows strong and membranous and cytoplasmic staining of COX-2 and (f) PCa Gleason 9 shows a very strong and diffuse staining of COX-2
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2005). Staining intensity was correlated to Gleason 
score (p=0.011) in which COX-2 expression was found 
significantly increased together with Gleason score (Table 
4). There is a significant relationship seen between age 
group and COX-2 expression in BPH cases but none in PCa 
cases. There is no significant association between COX-2 
expression and PSA level and tumour amount (Table 4). 
 COX-2 has been extensively studied in various disease 
and cancer including prostate cancer. In these current 
studies, COX-2 expression level was found significantly 
different in normal, BPH and PCa tissues. None of the 
normal cases showed strong COX-2 expression whereas 
all (100%) of normal prostate cases showed weak COX-2 
expression (1+ and 2+). In contrast, more than half (56%) 
of PCa cases showed strong COX-2 expression (3+ and 4+). 
The increased intensity of COX-2 staining was also seen 
with the increased of Gleason score (Figure 1(c)-1(f)). This 
finding suggested, increased COX-2 expression has a role 
in the aggressiveness of tumour phenotype in PCa. The 
present finding was closely similar to the study done by 
Yoshimura et al. (2000), who found that COX-2 expression 
was very weak in all BPH and normal prostate samples. 
They also found, a very strong COX-2 expression in the 
high grades of prostate adenocarcinomas. High COX-2 
expression in PCa cases of this study was also paralleled to 
the latest study done in Egypt. They found that 86.7% of 
PCa cases showed strong COX-2 expression and PCa grade 
3 cases showed COX-2 expression stronger than those of 
grade 2 with statistically significant (Mostafa et al. 2009). 
Consistent with our results, many studies indicated that 
TABLE 4. Relationship between COX-2 expressions with clinicopathological parameters
Clinicopathological parameter COX-2 score
Total pLow expression 
(0 - 2+)
High expression 
(3+ - 4+)
Age group in BPH (mean 68.13±7.42)
 ≤ 68 years
 >68 years
30
54
10
6
40
60
0.043
Age group in PCa (mean 66.78±6.23)
 ≤ 66 years
 >66 years 
17
27
23
33
40
60
0.100
PSA (ng/mL)
 ≤ 4.0
 >4.0 
13
31
16
40
29
71
0.915
Gleason score
 ≤ 7
 >7 
36
8
38
18
74
26
0.011
Tumour amount (%)
 ≤ 5
 >5
20
24
15
41
35
65
0.052
TABLE 2. COX-2 staining pattern in normal, BPH and PCa cases
Staining pattern distribution
Case Membranous Cytoplasmic Diffuse 
(membranous + cytoplasmic)
Total
Normal
BPH
PCa
58 (92.1%)
76 (76%)
40 (40%)
5 (7.9%)
24 (24%)
32 (32%)
0 (0%)
0 (0%)
28 (28%)
63 (100%)
100 (100%)
100 (100%)
TABLE 3. COX-2 staining pattern in different grades of PCa
Distribution of staining pattern 
Total pGleason score Membranous Cytoplasmic Granular
6
7
8
9
32 (86.5%)
8(21.6%)
0(0%)
0(0%)
5 (13.5%)
21(56.8%)
4(40%)
2(12.5%)
0 (0%)
8(21.6%)
6(60%)
14(87.5%)
37 (100%)
37 (100%)
10 (100%)
16 (100%)
<0.001
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COX-2 was expressed at high levels in PCa (Gupta et al. 
2000; Liu et al. 2000; Wang et al. 2005).
 In term of staining patterns, COX-2 staining pattern 
was differently expressed in normal, BPH and PCa cases. 
We found that, COX-2 was expressed from membranous, 
cytoplasmic to diffuse staining patterns in various prostate 
tissues. Interestingly, the membranous pattern expression 
was found in the luminal glandular cells of the majority 
of normal (92.1%) and BPH (76%) cases. In contrast, 
COX-2 expression in PCa was marginally greater tumour 
cells than in benign and normal cells. COX-2 expression 
in majority of PCa cases was showed heterogeneous from 
moderate to strong cytoplasmic and diffuse staining 
pattern. The pattern shift from membranous to diffuse 
within the PCa cases in which it was correlated with 
increasing tumour grade (p<0.001). This finding was 
similar to the study done by Madaan et al. (2000) which 
they reported that aggressiveness of PCa was related to the 
staining pattern. They added, intracellular localization of 
COX-2 in the epithelial cells in BPH and PCa was different. 
PCa predominantly localized in the cytoplasmic region 
whereas BPH was mainly at the membrane region. This 
study supported Madaan et al. (2008) study in which 
Gleasons 8 and 9 showed more diffuse staining patterns 
as compared to the Gleason 6 which was membranous 
staining pattern. Naturally, COX-2 was expressed in cell 
membrane in the luminal cells of BPH, which is consistent 
with the co-localization of the enzyme and its substrate. 
Linoleic acid is the major constituents of the lipid bilayer 
of the cell membrane and is a precursor of arachidonic acid, 
from which prostaglandins are, synthesized (Gottard 1986). 
This feature of COX-2 expression was lost during cellular 
transformation, as the expression became cytoplasmic and 
diffused (Madaan et al. 2008).
 In addition, we also found that Gleason >7 cases 
showed higher COX-2 expression level than those cases 
with Gleason score ≤ 7 with statistically significant 
(p=0.01). Increased level of COX-2 expression in high 
grade PCa (Gleason > 7) was generally in line with 
previous studies (Gupta et al. 2000; Madaan et al. 2000; 
Wang et al. 2005; Yoshimura et al. 2000). However, there 
were discrepancies reported by Zha et al. (2001), as they 
mentioned that COX-2 expression was not consistently 
elevated in PCa but in proliferative inflammatory atrophy 
(PIA) of prostate, and furthermore, the extent of positive 
staining did not correlate with Gleason score. Another study 
also reported the same finding as Zha et al. (2001) although 
they found high COX-2 expression in high grade prostate 
tumour cells (Shappell et al. 2001). Age of BPH group was 
found correlated with COX-2 expression (p=0.043), with 
the expression showed consistently low level in almost 
all BPH tissues but significantly increased with aging. In 
contrast, age of PCa group was not found correlated with 
COX-2 expression (p=0.100). Furthermore, there was no 
significant association found between PSA level and tumour 
amount with the COX-2 expression. Although, PSA has been 
used for a long time in diagnostic consideration on PCa, 
however its sensitivity was not perfect enough to be used 
alone. PSA generally fails as a marker to evaluate the extent 
of tumor phenotype for prostate cancer (Rodney 2005). 
Tumour amount did not show any significant finding with 
the level of COX-2 expression, it is suggested due to the 
variability in interpretation of the tumour amount itself by 
pathologists during the histopathological procedure.
 In addition, to prove evidence that COX-2 has 
a significant role in the prostate carcinogenesis and 
aggressiveness, we also provide different views in animal 
and cell culture studies that showed the same finding as 
what we have obtained. Hla et al. (1999) mentioned that 
prostaglandin (PG) production generally was elevated 
in cancer cells, suggesting that COX-2 induction has the 
potential in promoting tumour growth and its progression. 
Animal study showed COX-2/Apc∆716 double-gene 
‘knockout’ mice have lesser and smaller intestinal polyps 
than Apc∆716 knockout mice. This study clearly showed that 
COX-2 is responsible for the aggressiveness of intestinal 
polyps phenotype in mice (Oshima et al. 1996). Liu et 
al. (1998) reported that a selective COX-2 inhibitor has 
a potential inducing apoptosis and down-regulates bcl-
2 expression in prostate cancer cell line (LNCaP). Latest 
study done by Hao et al. (2011) found that prostate cancer 
cell growth can be inhibited by directly inhibiting COX-2 
expression. According to the report, tumour-supressive 
miRNA (miR-101) has a direct effect on inhibition of COX-2 
expression. Besides, exogenous miR-101 also suppresses 
the proliferation and growth of prostate cancer cells in vivo 
and in vitro.
 There are many evidences by which COX-2 plays a 
role in carcinogenesis either direct or indirect mechanism 
may be involved in prostate cancer development and 
progression. Many studies have been discussing on how 
over-expression of COX-2 can promote cell proliferation and 
metastasis of cancer cells (Hla et al. 1999). Prostaglandin 
production generally was elevated in most of cancer cells. 
Additionally, induction of COX-2 expression induces 
networks of regulatory factors that influence cell survival, 
growth and differentiation (Coussens & Werb 2001). COX-
2 also induces vascularization (Chu et al. 2003; Leung 
et al. 2002; Wang et al. 2005). This process is important 
for tumour growth and metastases. Wang et al. (2005) 
mentioned that proinflammatory cytokines, released by 
T-lymphocyte and macrophages, up-regulate COX-2 in 
adjacent tumour cells and stimulate the angiogenesis in 
stromal tissues within prostate cancer. Direct relationship 
of angiogenesis between COX-2 and PCa was also consistent 
with observation in liver, colon, endometrial and breast 
tumour (Chapple et al. 2002; Davies et al. 2003; Fujiwaki 
et al. 2002; Rahman et al. 2001). Over-expression of 
COX-2 has also been implicated in up-regulation of bcl-2 
expression and this leads to decrease in apoptosis (Tsujii et 
al. 1998). In contrast, down-regulation of bcl-2 expression 
was reported when it is treated with a selective COX-2 
inhibitor (NS-398) (Liu et al. 1998). Consistent with Liu 
et al. (1998), the latest study demonstrates that colorectal 
cancer cells undergo greater apoptosis as a result of 
exposure to specific COX-2 inhibitor in vivo (Rahman et 
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al. 2012). On the other hand, COX-2 over-expression was 
also induced to the decreased expression of E-cadherin and 
thus promoting loss of cell-to-cell adhesion which would 
increase the chance in invasiveness of tumour (Tsujii & 
DuBois 1995). Generally, E-cadherin plays a major part 
in the establishment and maintenance of intracellular 
adhesion and tissue architecture. Loss of E-cadherin 
mediated intercellular adhesion seems to be an important 
contributor factor in tumour metastasis. 
CONCLUSION
In conclusion, the study proved that the over-expression 
of COX-2 has a significant association with prostate 
cancer and higher grade tumour. Although we did not see 
a significant association between COX-2 expression and 
clinicopathological parameters such as age, PSA and tumour 
amount, there was a clear significant finding that showed 
COX-2 expression was over-expressed in high grade cancer 
specimens. Additionally, the shift from membranous to 
cytoplasmic and diffuse staining pattern was correlated 
with neoplastic progression of prostate tissues from 
normal to benign and malignant prostate tissues. There 
are strong arguments and suggestions that COX-2 should 
be evaluated further as one of the potential therapeutic 
targets for prostate cancer or even other types of cancers 
in Malaysia. We also hope that this study might be useful 
as a baseline data to other studies in order to develop the 
best prognostic marker for prostate cancer.
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